Bavarian Nordic A/S Q3 2026 Earnings Recap
Bavarian Nordic’s results and 2026 outlook were broadly steady, with shares down 0.2% after earnings. Travel Health growth and secured preparedness contracts supported the report, while the company flagged that its unusually high nine-month EBITDA margin reflects investment phasing, with more R&D and commercial spending expected in Q4.
The numbers
Reported results against what analysts expected.
Key takeaways
From the Q3 2026 earnings call.
- Nine-month revenue was just under DKK 4.9 billion, up 2% reported and more than 9% organically after adjusting for discontinued partnerships and foreign exchange.
- Travel Health grew 24% in the first nine months and 22% in Q3; excluding discontinued partnerships, nine-month growth was over 30%, led by rabies and supported by Vimkunya.
- Rabies sales in the U.S. market grew 36% in the first nine months versus the prior year, with management describing growth as accelerating.
- Nine-month EBITDA margin was close to 35%, with management attributing part of the level to the phasing of R&D and commercial investments into Q4.
- The company maintained its 2026 outlook: revenue of around DKK 6.1 billion, including approximately DKK 4 billion from Travel Health, and an EBITDA margin of around 32%; it also cited around DKK 2.4 billion secured for 2026 and DKK 900 million for 2027.
Track earnings for the stocks you own
Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.
Also published on November 17, 2026
This summary was written by AI from the official earnings call transcript. It is for information only and is not financial advice. For BAVA.CO's price history and fundamentals, see the BAVA.CO stock page.